MILAN ( – The biomedical logistics sector is regulated by the health authorities of various countries, so it is difficult to be threatened by small companies on the one hand and by large entities working on standardised structures on the other. “Bomi has clients with whom it has been operating for 15 years, so trust and expertise represent two important drivers in the relationship between supplier and customer”, explains the company’s CEO, Marco Ruini. In 2017 the group recorded 117.9 million of value of production (+ 17% on 2016), an adjusted ebitda of 11.3 million (+ 29%) and a net profit of 2.1 million euros. “We have invested in the ownership of transport, going against what were the beliefs of the sector, consolidating minorities and making acquisitions – continues Ruini – We are now present in Asia and South America, as well as in Europe, there are new operations and we have delegated for a further increase of 12 million if we find some companies that are particularly attractive”. On 10 May the company will present itself to investors in a dedicated Investor Day.